CStone receives CTA approval in China to start Phase I trial for FGFR4 inhibitor BLU-554 (CS3008)
SUZHOU, China, Jan. 29, 2019 /…
The Art & Science of Wellness
SUZHOU, China, Jan. 29, 2019 /…
CHENNAI, India, Jan. 25, 2019 …
REYKJAVIK, Iceland, Jan. 25, 2…
DARMSTADT, Germany, Jan. 24, 2…
Appointment Solidifies Strong …
SHANGHAI, Jan. 22, 2019 /PRNew…
Multilingual WordPress with WPML